|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Center for Research Resources (NCRR) |
|---|---|
| Collaborator: |
Arthritis Foundation |
| Information provided by: | National Center for Research Resources (NCRR) |
| ClinicalTrials.gov Identifier: | NCT00008749 |
Purpose
Systemic lupus erythematosus is an often devastating autoimmune disease which affects 1 in 2,000 women in the United States. Recently, several research laboratories have reported that a protein, named CD40-ligand (CD154), is overexpressed by a subset of white blood cells, called lymphocytes, in patients with lupus. Expression of CD154 appears critical to the generation of antibodies that cause disease in lupus. Blocking CD154 interactions in the immune system has been shown to decrease disease activity in animal models of lupus. We propose to study the regulation of CD154 in patients with lupus in hopes of inhibiting its abnormal and deleterious expression.
| Condition |
|---|
|
Lupus Erythematosus, Systemic |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Observational Model: Natural History |
| Official Title: | Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus |
Eligibility| Ages Eligible for Study: | 13 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion:
A diagnosis of systemic lupus erythematosus
Contacts and Locations| Contact: Randy Q Cron, MD, Ph.D. | 215-590-1844 |
| United States, Pennsylvania | |
| Children's Hospital of Philadelphia | Recruiting |
| Philadelphia, Pennsylvania, United States, 19104-4318 | |
| Contact: Randy Q Cron, M.D., Ph.D. 215-590-1844 | |
More Information
| ClinicalTrials.gov Identifier: | NCT00008749 History of Changes |
| Other Study ID Numbers: | NCRR-M01RR00240-1736 |
| Study First Received: | January 16, 2001 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Federal Government |
|
Lupus Erythematosus, Systemic Connective Tissue Diseases Autoimmune Diseases Immune System Diseases |